ABBOTT LABORATORIES— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$86.71B
↑+6.5% +$5.30Bvs FY2024
Total Liabilities
$16.50B
↑+16.5% +$2.34Bvs FY2024
Equity
$52.13B
↑+9.4% +$4.47Bvs FY2024
Cash
$8.52B
↑+11.9% +$906Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $86.71B | $81.41B |
| Current Assets | $26.00B | $23.66B |
| Cash | $8.52B | $7.62B |
| ST Investments | $417M | $351M |
| Receivables | $7.93B | $6.92B |
| Inventory | $6.49B | $6.19B |
| Other Current | $2.64B | $2.57B |
| Non-Current Assets | $60.72B | $57.76B |
| PPE | $11.82B | $10.66B |
| Goodwill | $24.04B | $23.11B |
| Intangibles | $5.53B | $6.65B |
| Investments | $918M | $886M |
| Other Non-Current | $18.42B | $16.46B |
| Total Liab+Eq | $52.13B | $47.66B |
| Current Liab. | $16.50B | $14.16B |
| Accounts Payable | $0 | $0 |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $16.50B | $14.16B |
| Non-Current Liab. | $0 | $0 |
| Long-Term Debt | $12.93B | $14.13B |
| Other LT Liab. | $0 | $0 |
| Equity | $52.13B | $47.66B |
| Retained Earnings | $49.78B | $47.26B |
| Other Equity | $2.35B | $403M |
QuarterCharts · SEC EDGAR data · ABT · Comparing FY2025 vs FY2024